Oral imatinib treatment reduces early fibrogenesis but does not prevent progression in the long term

被引:74
作者
Neef, M
Ledermann, M
Saegesser, H
Schneider, V
Widmer, N
Decosterd, LA
Rochat, B
Reichen, J [1 ]
机构
[1] Univ Bern, Inst Clin Pharmacol, Bern, Switzerland
[2] Univ Lausanne Hosp, CHU Vaudois, Div Clin Pharmacol, Lausanne, Switzerland
[3] CHU Vaudois, Quantitat Mass Spectrometry Facil, CH-1011 Lausanne, Switzerland
关键词
liver cirrhosis; experimental; bile duct-ligation; hepatic stellate cells; imatinib; platelet-derived growth factor; platelet-derived growth factor beta receptor;
D O I
10.1016/j.jhep.2005.06.015
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aims: Transactivated hepatic stellate cells (HSCs) represent the key source of extra cellular matrix (ECM) in fibrotic liver. Imatinib, a potent inhibitor of the PDGF receptor tyrosine kinase, reduces HSC proliferation and fibrogenesis when treatment is initiated before fibrosis has developed. We tested the antifibrotic potential of imatinib in ongoing liver injury and in established fibrosis. Methods: BDL-rats were gavage fed with 20 mgAkg/d imatinib either early (days 0-21) or late (days 22-35) after BDL. Untreated BDL-rats served as controls. ECM and activated HSCs were quantified by morphometry. Tissue activity of MMP-2 was determined by gelatin zymography. mRNA expression of TIMP-1 and procollagen alpha 1(I) were measured by RT-PCR. Liver tissue concentration of imatinib was measured by tandem mass spectrometry. Results: Early imatinib reduced ECM formation by 30% (P = 0.0455) but left numbers of activated HSCs and procollagen I expression unchanged. MMP-2 activity and TIMP-1 expression were reduced by 50%. Late imatinib treatment did not alter histological or molecular markers of fibrogenesis despite high imatinib tissue levels. Conclusions: The antifibrotic effectiveness of imatinib is limited to the early phase of fibrogenesis. In ongoing liver injury other mediators most likely compensate for the inhibited PDGF effect. (c) 2005 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:167 / 175
页数:9
相关论文
共 24 条
[1]  
[Anonymous], 1998, Biochim. Biophys. Acta
[2]   Extracellular matrix degradation and the role of hepatic stellate cells [J].
Benyon, RC ;
Arthur, MJP .
SEMINARS IN LIVER DISEASE, 2001, 21 (03) :373-384
[3]  
BIECKER E, 2005, J PHARMACOL EXP THER, V15, P15
[4]   Dominant-negative soluble PDGF-β receptor inhibits hepatic stellate cell activation and attenuates liver fibrosis [J].
Borkham-Kamphorst, E ;
Herrmann, J ;
Stoll, D ;
Treptau, J ;
Gressner, AM ;
Weiskirchen, R .
LABORATORY INVESTIGATION, 2004, 84 (06) :766-777
[5]   Inhibitory effect of soluble PDGF-β receptor in culture-activated hepatic stellate cells [J].
Borkham-Kamphorst, E ;
Stoll, D ;
Gressner, AM ;
Weiskirchen, R .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2004, 317 (02) :451-462
[6]  
Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139
[7]  
Friedman SL, 2001, SEMIN LIVER DIS, V21, P307
[8]  
Gentilini A, 2001, J HEPATOL, V34, P7
[9]   Phosphatidylinositol-3 kinase and extracellular signal-regulated kinase mediate the chemotactic and mitogenic effects of insulin-lice growth factor-I in human hepatic stellate cells [J].
Gentilini, A ;
Marra, F ;
Gentilini, P ;
Pinzani, M .
JOURNAL OF HEPATOLOGY, 2000, 32 (02) :227-234
[10]   Expression of platelet-derived growth factor in newly formed cholangiocytes during experimental biliary fibrosis in rats [J].
Grappone, C ;
Pinzani, M ;
Parola, M ;
Pellegrini, G ;
Caligiuri, A ;
DeFranco, R ;
Marra, F ;
Herbst, H ;
Alpini, G ;
Milani, S .
JOURNAL OF HEPATOLOGY, 1999, 31 (01) :100-109